Aliases & Classifications for Wells Syndrome

MalaCards integrated aliases for Wells Syndrome:

Name: Wells Syndrome 50 56 69
Eosinophilic Cellulitis 50 56
Bullous Cellulitis with Eosinophilia 50
Wells' Syndrome 50

Characteristics:

Orphanet epidemiological data:

56
wells syndrome
Inheritance: Not applicable; Prevalence: <1/1000000 (Worldwide); Age of onset: Adult; Age of death: normal life expectancy;

Classifications:

Orphanet: 56  
Rare skin diseases


External Ids:

Orphanet 56 ORPHA901
MESH via Orphanet 43 C536693
UMLS via Orphanet 70 C0343101
ICD10 via Orphanet 34 L98.3
ICD10 33 L98.3

Summaries for Wells Syndrome

NIH Rare Diseases : 50 wells syndrome is a rare eosinophilic disorder that primarily affects the skin. affected people typically develop a skin rash that is often proceeded by itching or burning skin. the rash consists of raised, red, swollen areas that may be warm to the touch. the symptoms generally come on rapidly and may last four to eight weeks. in some cases, the rash may recur (occur frequently or repeatedly) for years. the exact underlying cause of wells syndrome is currently unknown; however, some scientists believe that it may be an autoimmune reaction. oral or topical corticosteroids are commonly used to treat wells syndrome, although antifungal drugs, antibiotics, immunosuppressants, and/or antihistamines have also been used with varying degrees of success. last updated: 4/27/2015

MalaCards based summary : Wells Syndrome, also known as eosinophilic cellulitis, is related to muckle-wells syndrome and familial cold-induced inflammatory syndrome 1, and has symptoms including pruritus, cellulitis and edema. An important gene associated with Wells Syndrome is NLRP3 (NLR Family Pyrin Domain Containing 3), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Prednisone and lanreotide have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and heart, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and homeostasis/metabolism

CDC : 3 Many people in the United States receive their water from private ground water wells. EPA regulations that protect public drinking water systems do not apply to privately owned wells. As a result, owners of private wells are responsible for ensuring that their water is safe from contaminants. Here you may find information on the basics of wells, proper methods of siting and location for wells, all about testing and how often to test a well, proper treatment of wells and maintenance of wells , information on well retirement, common diseases and contaminants associated with wells, emergency treatment of wells, and answers to frequently asked questions about wells.

Related Diseases for Wells Syndrome

Diseases related to Wells Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 180)
id Related Disease Score Top Affiliating Genes
1 muckle-wells syndrome 32.5 CRP IL1B IL1R1 MEFV NLRP3 TNFRSF1A
2 familial cold-induced inflammatory syndrome 1 30.4 IL1B IL1R1 MEFV NLRP3 TNFRSF1A
3 churg-strauss syndrome 30.2 CXCL8 IL1B IL5
4 lymphoma 29.7 IL1B IL2 IL5 MEFV
5 asthma 28.1 CXCL8 IL1B IL1R1 IL2RA IL5 RNASE3
6 hay-wells syndrome 12.2
7 ptosis coloboma mental retardation 10.8 MEFV NLRP3
8 acute neonatal citrullinemia type i 10.8 MEFV TNFRSF1A
9 acute megakaryoblastic leukemia without down syndrome 10.8 MEFV TNFRSF1A
10 ciliary body cancer 10.7 IL1B NLRP3
11 cryopyrin-associated periodic syndrome 10.7
12 tabatznik syndrome 10.7 IL1B MEFV
13 papillary follicular thyroid adenocarcinoma 10.7 IL5 RNASE3
14 yao syndrome 10.6 IL1B MEFV NLRP3
15 noma 10.6 IL1B MEFV NLRP3
16 leigh syndrome with leukodystrophy 10.6 MEFV TNFRSF1A
17 oculomotor nerve paralysis 10.6 CXCL8 IL1B
18 mycobacterium xenopi 10.6 CXCL8 NLRP3
19 angiomyoma 10.6 IL5 NLRP3 RNASE3
20 multiple sclerosis 5 10.6 MEFV NLRP3 TNFRSF1A
21 congenital diaphragmatic hernia 10.5 CXCL8 IL2
22 graft-versus-host disease, protection against 10.5 IL2 IL2RA
23 walker dyson syndrome 10.5 IL1B IL1R1 NLRP3
24 milk allergy 10.5 IL1B IL1R1 NLRP3
25 toxic diffuse goiter 10.5 IL5 RNASE3
26 sinusitis 10.5 CXCL8 IL1B NLRP3
27 lip cancer 10.5 CXCL8 MEFV NLRP3
28 asbestosis 10.4 CXCL8 IL1B NLRP3
29 giant axonal neuropathy 2 10.4 IL1B IL1R1 NLRP3
30 central nervous system origin vertigo 10.4 IL2 IL2RA RNASE3
31 marasmus 10.4 IL5 RNASE3
32 keloids 10.4 IL1B IL1R1 IL1RAPL2
33 x-linked intellectual disability, van esch type 10.4 IL2 IL5 RNASE3
34 congenital nystagmus 10.4 IL1B MEFV NLRP3 TP63
35 common peroneal nerve lesion 10.4 CXCL8 IL1B IL5
36 carcinoma arising in nasal papillomatosis 10.4 CXCL8 IL1B IL2RA
37 inflamed seborrheic keratosis 10.4 IL2 IL5 RNASE3
38 spirillary rat-bite fever 10.4 CXCL8 IL2
39 exophthalmos 10.4 CXCL8 IL5 RNASE3
40 skin disease 10.4 CXCL8 IL5 RNASE3
41 gliosarcoma 10.4 IL1B IL1R1 TNFRSF1A
42 premature ovarian failure 12 10.4 CXCL8 IL1B RNASE3
43 acral lentiginous melanoma 10.4 IL1B IL2 IL2RA
44 adiaspiromycosis 10.4 MEFV NLRP3
45 eyelid neoplasm 10.4 CXCL8 IL5 RNASE3
46 acute contagious conjunctivitis 10.4 CXCL8 IL5 RNASE3
47 dehydration polycythemia 10.3 CXCL8 IL5 RNASE3
48 amyotrophic lateral sclerosis type 10 10.3 CXCL8 IL1B IL2
49 pelvic varices 10.3 CXCL8 IL5 RNASE3
50 conjunctival concretion 10.3 CXCL8 IL1B IL5

Graphical network of the top 20 diseases related to Wells Syndrome:



Diseases related to Wells Syndrome

Symptoms & Phenotypes for Wells Syndrome

Human phenotypes related to Wells Syndrome:

56 32 (show all 9)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 pruritus 56 32 hallmark (90%) Very frequent (99-80%) HP:0000989
2 cellulitis 56 32 hallmark (90%) Very frequent (99-80%) HP:0100658
3 edema 56 32 frequent (33%) Frequent (79-30%) HP:0000969
4 eosinophilia 56 32 frequent (33%) Frequent (79-30%) HP:0001880
5 abnormal blistering of the skin 56 32 frequent (33%) Frequent (79-30%) HP:0008066
6 skin vesicle 56 32 frequent (33%) Frequent (79-30%) HP:0200037
7 fever 56 32 occasional (7.5%) Occasional (29-5%) HP:0001945
8 arthralgia 56 32 occasional (7.5%) Occasional (29-5%) HP:0002829
9 vasculitis 56 Excluded (0%)

GenomeRNAi Phenotypes related to Wells Syndrome according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.72 IL2RA NLRP3 TNFRSF1A CXCL8 IL1B IL2
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.72 IL2RA NLRP3 TNFRSF1A TP63 CXCL8 IL1B

MGI Mouse Phenotypes related to Wells Syndrome:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.18 IL1R1 RACK1 TNFRSF1A IL2 TP63 IL2RA
2 immune system MP:0005387 10.06 NLRP3 IL1R1 TNFRSF1A IL2 TP63 IL2RA
3 digestive/alimentary MP:0005381 9.95 NLRP3 TNFRSF1A IL2 IL2RA IL5 FGFR2
4 integument MP:0010771 9.86 IL1B NLRP3 RACK1 IL1R1 TNFRSF1A FGFR2
5 liver/biliary system MP:0005370 9.7 NLRP3 IL1R1 TNFRSF1A IL2 IL5 FGFR2
6 neoplasm MP:0002006 9.5 IL1R1 TNFRSF1A IL2 IL5 FGFR2 IL1B
7 respiratory system MP:0005388 9.17 IL1R1 TNFRSF1A IL2 IL2RA IL5 FGFR2

Drugs & Therapeutics for Wells Syndrome

Drugs for Wells Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1166)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 53-03-2 5865
2 lanreotide Approved Phase 4 108736-35-2
3
Somatostatin Approved Phase 4,Phase 2 38916-34-6, 51110-01-1 53481605
4
Acetaminophen Approved Phase 4,Phase 2,Early Phase 1 103-90-2 1983
5
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
6
Amlodipine Approved Phase 4,Phase 3,Phase 2 88150-42-9 2162
7
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
8
Valsartan Approved, Investigational Phase 4,Phase 2 137862-53-4 60846
9
Menthol Approved Phase 4,Phase 3,Phase 2 2216-51-5 16666
10
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 657-24-9 14219 4091
11
Dinoprostone Approved Phase 4 363-24-6 5280360
12
Aripiprazole Approved, Investigational Phase 4,Phase 2 129722-12-9 60795
13
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 134678-17-4 60825
14
Stavudine Approved, Investigational Phase 4,Phase 2,Phase 3 3056-17-5 18283
15
Ticagrelor Approved Phase 4,Phase 3,Phase 2 274693-27-5 9871419
16
Ticlopidine Approved Phase 4,Phase 3,Phase 2 55142-85-3 5472
17
Iloprost Approved, Investigational Phase 4 78919-13-8 6443959
18
Didanosine Approved Phase 4,Phase 3 69655-05-6 50599
19
Efavirenz Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 154598-52-4 64139
20
Amitriptyline Approved Phase 4,Phase 2,Phase 3 50-48-6 2160
21
Cyclobenzaprine Approved Phase 4 303-53-7 2895
22
Moxonidine Approved Phase 4 75438-57-2 4810
23
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
24
Propafenone Approved Phase 4 54063-53-5 4932
25
Sotalol Approved Phase 4 959-24-0, 3930-20-9 5253
26
Cosyntropin Approved Phase 4 16960-16-0 16129617
27
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 51-43-4 5816
28
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-23-7 5754 657311
29 Racepinephrine Approved Phase 4,Phase 2,Phase 3,Phase 1
30
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-84-3 187
31
Udenafil Approved, Investigational Phase 4 268203-93-6 6918523
32
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177
33
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
34
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
35
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 128794-94-5 5281078
36
Mycophenolic acid Approved Phase 4,Phase 3,Phase 1,Phase 2 24280-93-1 446541
37
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
38
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53123-88-9 5284616 6436030 46835353
39
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 104987-11-3 445643 439492
40
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
41
Milnacipran Approved Phase 4,Phase 3,Phase 2,Phase 1 92623-85-3 65833
42
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
43
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1 7439-89-6 23925
44
Mannitol Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 69-65-8 453 6251
45
Pancrelipase Approved Phase 4,Phase 2 53608-75-6
46
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2 9005-49-6 772 46507594
47
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-02-2 5743
48
Eptifibatide Approved, Investigational Phase 4,Phase 3 188627-80-7 123610
49
Zinc Approved Phase 4,Phase 2,Phase 1,Early Phase 1 7440-66-6 32051 23994
50
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 155213-67-5 392622

Interventional clinical trials:

(show top 50) (show all 2738)

id Name Status NCT ID Phase Drugs
1 Effect of Vitamin D on Metabolic Parameters in Patients With the Metabolic Syndrome Unknown status NCT01237769 Phase 4 Vitamin D3
2 Low Dose Steroids in the Treatment of Nephrotic Syndrome Relapse Unknown status NCT02216747 Phase 4 prednisone 60 mg/meter square Body Surface Area;prednisone 45 mg;prednisone 30 mg
3 Treatment of the Dumping Syndrome With Lanreotide Autogel® Unknown status NCT00543179 Phase 4 Somatuline (Lanreotide Autogel®)
4 Close Kinect Chain Exercise With Kinesio Taping in the Management of Patellofemoral Pain Syndrome Unknown status NCT02241148 Phase 4 Acetaminophen 500mg
5 The Effects of Continuous Positive Airway Pressure on Overlap Syndrome Unknown status NCT00914264 Phase 4
6 Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients Unknown status NCT00871845 Phase 4 Orlistat
7 PROMAD: Predicting Therapeutic Outcome of Mandibular Advancement Device Treatment in Obstructive Sleep Apnea Unknown status NCT01532050 Phase 4
8 Regression of Fatty Heart by Valsartan Therapy Unknown status NCT00745953 Phase 4 Valsartan;Hydrochlorothiazide
9 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
10 CT Coronary Angiogram Versus Traditional Care in Emergency Department Assessment of Potential ACS Unknown status NCT00933400 Phase 4
11 Metformin and Gestational Diabetes in High-risk Patients: a RCTs Unknown status NCT00883259 Phase 4 Metformin
12 The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain Unknown status NCT01417923 Phase 4 vitamin D
13 Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis Unknown status NCT01119014 Phase 4 Aripiprazole;Quetiapine
14 Study on the Antiviral Therapy and Immune Reconstitution of Chinese HIV/AIDS Patients Unknown status NCT00872417 Phase 4 first line ARV (3TC+NVP+D4T or 3TC+NVP+AZT);second line ARV therapy (3TC+TDF+LPV/RTV)
15 Comparing Ticagrelor and Clopidogrel Pharmacodynamics After Thrombolysis Unknown status NCT02048085 Phase 4 Ticagrelor;Clopidogrel
16 Effects of Iloprost Treatment in Adult Patients With Pulmonary Arterial Hypertension Related to Congenital Heart Disease Unknown status NCT01383083 Phase 4
17 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
18 Once Daily 3TC, Efavirenz and ddI for HIV Infection Unknown status NCT00214435 Phase 4 once daily minimum 3-drug regimen of anti-retroviral medications
19 Cyclobenzaprine Extended Release (ER) for Fibromyalgia Unknown status NCT01041495 Phase 4 cyclobenzaprine ER (AMRIX);placebo
20 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
21 Study of the Effect of Moxonidine and Diet on Sympathetic Functions in Young Adults With Obesity Unknown status NCT01180231 Phase 4 Moxonidine (Physiotens)
22 Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation Unknown status NCT02145546 Phase 4 Amiodarone;Propafenone;Sotalol
23 Determination of Method-specific Normal Cortisol and Adrenal Hormone Responses to the Short Synacthen Test Unknown status NCT00851942 Phase 4 Synacthen (Tetracosactrin)
24 Botulinum Toxin A for Treatment of Catocholamine Induced Finger Necrosis Unknown status NCT01500668 Phase 4 Botox;Placebo
25 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
26 Understanding of Chest Pain in Microvascular Disease Proved by Cardiac Magnetic Resonance Image Unknown status NCT01769482 Phase 4 Udenafil;placebo
27 Vitamin D and Glucose Metabolism in Pediatrics Unknown status NCT01386736 Phase 4 Vitamin D drops;Placebo drops
28 A Prospective Randomized Study Comparing Radiofrequency Energy With Cryoenergy Unknown status NCT00773539 Phase 4
29 Clinical Study to Evaluate the Efficacy of Anakinra in Patients With Rheumatoid Arthritis and Diabetes Unknown status NCT02236481 Phase 4 Anakinra;TNF alpha inhibitors
30 Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics Unknown status NCT00845936 Phase 4 Metformin
31 Evaluation of the Effects of Laying Early a Gastric Band on the Prevention of Morbid Obesity Randomized Checked Against Standard Management of Obesity in This Population. Unknown status NCT01700738 Phase 4
32 Korean AMADEUS Study Unknown status NCT01239849 Phase 4 Atorvastatin, 10mg, 20mg, 40mg
33 Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant Unknown status NCT02084446 Phase 4 Everolimus;Very Low Tacrolimus;Low Tacrolimus;Steroids;Thymoglobulin;Sodium Mycophenolate
34 Evaluating Results of Neusidl Corneal Inserter in Descemet's Stripping Automated Endothelial Keratoplasty (DSAEK) Unknown status NCT01357122 Phase 4
35 Study of Fibromyalgia Treated With Milnacipran Unknown status NCT01125423 Phase 4 Milnacipran
36 Pacing of the Atria in Sick Sinus Syndrome Trial Preventive Strategies for Atrial Fibrillation Completed NCT00161538 Phase 4
37 Safety and Efficacy of Aripiprazole and Ziprasidone Among Schizophrenic Patients With Metabolic Syndrome Completed NCT01714011 Phase 4 Ziprasidone;Aripiprazole
38 Effect of Nicotinic Acid on Cardiovascular Risks Indices in Polycystic Ovary Syndrome Completed NCT01118598 Phase 4 tredaptive (nicotinic acid/ laropiprant);placebo
39 Improving the Management of Acute Coronary Syndromes in the Emergency Department Completed NCT01563250 Phase 4
40 Biseko Versus Albumin in Systemic Inflammatory Response Syndrome (SIRS) Patients Completed NCT00708747 Phase 4 Albumin (5% serum-protein solution containing immunoglobulins);Biseko
41 An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder Completed NCT00961298 Phase 4 Duloxetine
42 First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study Completed NCT01419249 Phase 4
43 Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome Post Marketing Commitment Study Completed NCT01668667 Phase 4 GSK1838262 600 mg;GSK1838262 450 mg;GSK1838262 300 mg;GSK1838262 Placebo match
44 Defining the Optimal Hormonal Replacement Therapy in Turner Syndrome Completed NCT00134745 Phase 4 estradiol
45 Restless Legs Syndrome With Iron Deficiency or Anaemia in the 3rd Trimester of Pregnancy Completed NCT01245777 Phase 4 ferric carboxymaltose
46 The Effects of Cilnidipine on Metabolic Syndrome Improvement Completed NCT00325936 Phase 4 Cilnidipine
47 Efficacy and Safety of Memantine Hydrochloride in Enhancing the Cognitive Abilities of Young Adults With Down Syndrome Completed NCT01112683 Phase 4 Memantine;Placebo
48 rHGH and Intestinal Permeability in Intestinal Failure Completed NCT01380366 Phase 4 Somatropin
49 Galantamine Effects in Patients With Metabolic Syndrome Completed NCT02283242 Phase 4 Galantamine;Placebo (for galantamine)
50 Irritable Bowel Syndrome Evaluation and Treatment in Primary Care Completed NCT01641341 Phase 4 Bifidobacterium infantis;Pancrelipase;Nitazoxanide;Placebo

Search NIH Clinical Center for Wells Syndrome

Genetic Tests for Wells Syndrome

Anatomical Context for Wells Syndrome

MalaCards organs/tissues related to Wells Syndrome:

39
Myeloid, Bone, Heart, Brain, Testes, Bone Marrow, Ovary

Publications for Wells Syndrome

Articles related to Wells Syndrome:

(show top 50) (show all 212)
id Title Authors Year
1
Endometriosis in the setting of Muckle-Wells syndrome treated with an IL-1I^ antagonist. ( 28508753 )
2017
2
Muckle-Wells syndrome: clinical perspectives. ( 28744167 )
2017
3
Wells' Syndrome Successfully Treated with Colchicine. ( 28868003 )
2017
4
Periodic fever: From Still's disease to Muckle-Wells syndrome. ( 28583784 )
2017
5
Muckle-Wells syndrome in the setting of basal cell nevus syndrome. ( 28686751 )
2017
6
Bullous Pesentation of Idiopathic Wells Syndrome (Eosinophilic Cellulitis). ( 28920134 )
2017
7
Placental Transfer of Canakinumab in a Patient with Muckle-Wells Syndrome. ( 28386702 )
2017
8
A Novel Mutation in the Pyrin Domain of the NOD-like Receptor Family Pyrin Domain Containing Protein 3 in Muckle-Wells Syndrome. ( 28229991 )
2017
9
Wells Syndrome with Bullous Lesions. ( 28351790 )
2017
10
Wells syndrome associated with lung cancer. ( 28951508 )
2017
11
Wells syndrome. ( 27767278 )
2016
12
Muckle-Wells Syndrome: A Case Report with an NLRP3 T348M Mutation. ( 27435956 )
2016
13
Treatment of eosinophilic cellulitis (Wells syndrome) - a systematic review. ( 27357601 )
2016
14
Wells' syndrome with a clinicopathological correlation associated with mantle-cell lymphoma. ( 26999270 )
2016
15
Muckle-Wells syndrome in Chinese patients: a single center case series. ( 28028683 )
2016
16
Influenza Vaccination as a Novel Trigger of Wells Syndrome in a Child. ( 25894853 )
2015
17
Wells syndrome associated with chronic lymphocytic leukemia. ( 26375230 )
2015
18
Budget Impact Analysis of Canacinumab In The Treatment of Patients With Muckle-Wells Syndrome In The Russian Federation. ( 26533715 )
2015
19
Wells' Syndrome Mimicking Facial Cellulitis: A Report of Two Cases. ( 26120307 )
2015
20
Muckle-Wells syndrome in an Indian family associated with NLRP3 mutation. ( 25766347 )
2015
21
Idiopathic Hypereosinophilic Syndrome With Cutaneous Manifestations and Flame Figures: A Spectrum of Eosinophilic Dermatoses Whose Features Overlap With Wells' Syndrome. ( 25839890 )
2015
22
Early detection of sensorineural hearing loss in Muckle-Wells-syndrome. ( 26531310 )
2015
23
Muckle-Wells syndrome: a rare hereditary cryopyrin-associated periodic syndrome. ( 26218404 )
2015
24
IgG4-related disease of the paratestis in a patient with Wells syndrome: a case report. ( 25487870 )
2014
25
Syndrome in question. Hay-Wells syndrome. ( 24770526 )
2014
26
Eosinophilic leukocytoclastic vasculitis - a spectrum ranging from Wells' syndrome to Churg-Strauss syndrome? ( 25115356 )
2014
27
Muckle wells syndrome associated with multifocal clinically isolated syndrome. ( 24618190 )
2014
28
Wells syndrome. ( 24505587 )
2014
29
Eosinophilic cellulitis (Wells' syndrome) caused by a temporary henna tattoo. ( 25395929 )
2014
30
Life of Lesions in Eosinophilic Cellulitis (Wells' Syndrome)-A Condition That May Be Missed at First Sight. ( 25238447 )
2014
31
Recurrent paraneoplastic wells syndrome in a patient with metastatic renal cell cancer. ( 24945651 )
2014
32
Renal involvement in secondary amyloidosis of Muckle-Wells syndrome: marked improvement of renal function and reduction of proteinuria after therapy with human anti-interleukin-1I^ monoclonal antibody canakinumab. ( 24510061 )
2014
33
Wells syndrome: response to dapsone therapy. ( 25143695 )
2014
34
Muckle-Wells syndrome: individualized, reflare-guided dosing of the orphan drug canakinumab. ( 23745225 )
2013
35
Wells syndrome and its relationship to Churg-Strauss syndrome. ( 23786445 )
2013
36
Wells' syndrome associated with chronic myeloid leukaemia. ( 23147913 )
2013
37
Renal and thyroid amyloidosis secondary tocryopyrin-associated periodic syndrome(Muckle-Wells syndrome) (NLRP3 mutation). ( 23511763 )
2013
38
Chronic keratitis with intrastromal epithelioid histiocytes: a new finding in Muckle-Wells syndrome. ( 23187166 )
2013
39
Hearing loss in Muckle-Wells syndrome. ( 23440695 )
2013
40
Wells' syndrome associated with Churg-Strauss syndrome: correlation with mast cell distribution. ( 22998535 )
2013
41
Eosinophilic annular erythema is a peculiar subtype in the spectrum of Wells syndrome: a multicentre long-term follow-up study. ( 22731886 )
2013
42
Gigantic erythematous plaques with violaceous oedematous borders: a quiz. Wells' syndrome. ( 23572063 )
2013
43
Renal failure in Hay-Wells syndrome. ( 24231488 )
2013
44
Persistent hypereosinophilia with Wells syndrome. ( 22607377 )
2013
45
Challenges in diagnosing Muckle-Wells syndrome: Identifying two distinct phenotypes. ( 24127202 )
2013
46
Muckle-Wells syndrome: a treatable cause of congenital sensorineural hearing loss. ( 23909124 )
2013
47
Somatic NLRP3 mosaicism in Muckle-Wells syndrome. A genetic mechanism shared by different phenotypes of cryopyrin-associated periodic syndromes. ( 24326009 )
2013
48
Wells syndrome (eosinophilic cellulitis): Proposed diagnostic criteria and a literature review of the drug-induced variant. ( 24421864 )
2013
49
Muckle-Wells syndrome without mutation in exon 3 of the NLRP3 gene, identified by evidence of excessive monocyte production of functional interleukin 1I^ and rapid response to anakinra. ( 23889084 )
2013
50
Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens. ( 23718630 )
2013

Variations for Wells Syndrome

Expression for Wells Syndrome

Search GEO for disease gene expression data for Wells Syndrome.

Pathways for Wells Syndrome

Pathways related to Wells Syndrome according to GeneCards Suite gene sharing:

(show all 37)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.93 CRP CXCL8 FGFR2 IL1B IL1R1 IL2
2
Show member pathways
13.79 CXCL8 FGFR2 IL1B IL1R1 IL2 IL2RA
3
Show member pathways
13.59 CXCL8 FGFR2 IL1B IL1R1 IL2 IL2RA
4
Show member pathways
13.48 CXCL8 FGFR2 IL1B IL1R1 IL2 IL2RA
5
Show member pathways
13.34 CXCL8 FGFR2 IL1B IL1R1 IL2 IL2RA
6
Show member pathways
13.26 CXCL8 FGFR2 IL1B IL1R1 IL2 IL2RA
7
Show member pathways
13.12 CXCL8 FGFR2 IL1B IL1R1 IL2 IL2RA
8
Show member pathways
12.74 CXCL8 IL1B IL2 IL2RA IL5 RNASE3
9
Show member pathways
12.64 FGFR2 IL1B IL1R1 IL2 TNFRSF1A
10
Show member pathways
12.56 CXCL8 IL1B IL2 IL2RA NLRP3 RACK1
11
Show member pathways
12.55 IL1B IL1R1 IL2 IL2RA IL5
12 12.46 IL1B IL2 IL2RA TNFRSF1A
13 12.36 IL1R1 IL2 IL2RA TNFRSF1A
14
Show member pathways
12.09 CXCL8 IL1B IL2 IL5
15
Show member pathways
12.05 FGFR2 IL1B IL1R1 IL2 IL2RA IL5
16 11.96 CXCL8 IL1B IL1R1 IL2
17 11.92 IL2 IL2RA IL5
18
Show member pathways
11.89 IL1B IL1R1 IL2 IL2RA
19 11.82 CXCL8 IL1B IL1R1
20 11.78 IL1B IL1R1 IL2RA IL5
21 11.76 CXCL8 IL1B IL1R1 TNFRSF1A
22
Show member pathways
11.75 IL1B IL1R1 IL2 IL2RA IL5
23 11.74 CXCL8 IL2 IL5
24 11.7 CXCL8 IL1B NLRP3
25 11.61 CXCL8 IL1B IL5
26
Show member pathways
11.61 CXCL8 IL2 IL2RA IL5
27
Show member pathways
11.5 CXCL8 IL1B IL2 TNFRSF1A
28 11.47 IL2 IL2RA IL5
29 11.39 IL1B MEFV NLRP3
30
Show member pathways
11.38 IL2 IL2RA TNFRSF1A
31 11.36 CXCL8 IL1B IL1R1 TNFRSF1A
32 11.22 IL1B IL2 IL5
33 11.15 CXCL8 IL1B IL2 IL5
34 11.08 IL1B IL1R1 NLRP3
35 10.92 IL1B IL1R1 IL2 IL2RA IL5
36 10.83 IL1B IL5
37 10.78 IL2 IL2RA IL5 TNFRSF1A

GO Terms for Wells Syndrome

Cellular components related to Wells Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.32 CRP CXCL8 FGFR2 IL1B IL1R1 IL2

Biological processes related to Wells Syndrome according to GeneCards Suite gene sharing:

(show all 16)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of GTPase activity GO:0043547 9.95 FGFR2 IL2 IL2RA IL5 RACK1
2 apoptotic process GO:0006915 9.87 FGFR2 IL1B IL2RA NLRP3 RACK1 TNFRSF1A
3 MAPK cascade GO:0000165 9.8 FGFR2 IL1B IL2 IL2RA IL5
4 immune response GO:0006955 9.7 CXCL8 IL1B IL1R1 IL2 IL2RA IL5
5 positive regulation of T cell proliferation GO:0042102 9.69 IL1B IL2 IL2RA
6 cytokine-mediated signaling pathway GO:0019221 9.65 IL1B IL1R1 IL1RAPL2 IL5 TNFRSF1A
7 positive regulation of immunoglobulin secretion GO:0051024 9.54 IL2 IL5
8 positive regulation of ceramide biosynthetic process GO:2000304 9.52 RACK1 TNFRSF1A
9 regulation of establishment of endothelial barrier GO:1903140 9.49 IL1B TNFRSF1A
10 negative regulation of lymphocyte proliferation GO:0050672 9.48 IL2 IL2RA
11 interleukin-1 beta production GO:0032611 9.46 IL1B NLRP3
12 regulation of T cell homeostatic proliferation GO:0046013 9.43 IL2 IL2RA
13 squamous basal epithelial stem cell differentiation involved in prostate gland acinus development GO:0060529 9.37 FGFR2 TP63
14 negative regulation of inflammatory response GO:0050728 9.35 IL2 IL2RA MEFV NLRP3 TNFRSF1A
15 inflammatory response GO:0006954 9.23 CRP CXCL8 IL1B IL2RA IL5 MEFV
16 positive regulation of transcription from RNA polymerase II promoter GO:0045944 10.03 FGFR2 IL1B IL2 NLRP3 TNFRSF1A TP63

Molecular functions related to Wells Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.46 CXCL8 IL1B IL2 IL5
2 interleukin-1 receptor activity GO:0004908 8.96 IL1R1 IL1RAPL2
3 Ras guanyl-nucleotide exchange factor activity GO:0005088 8.92 FGFR2 IL2 IL2RA IL5

Sources for Wells Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....